- Home
- JAZZ
as 12-17-2024 4:00pm EST
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 6.5B | IPO Year: | 2007 |
| Target Price: | $173.93 | AVG Volume (30 days): | 539.6K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.04 | EPS Growth: | 458.10 |
| 52 Week Low/High: | $99.06 - $134.17 | Next Earning Date: | 11-06-2024 |
| Revenue: | $3,992,712,000 | Revenue Growth: | 5.23% |
| Revenue Growth (this year): | 7.51% | Revenue Growth (next year): | 6.82% |
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | JAZZ | Chairman & CEO | Dec 2 '24 | Sell | $121.17 | 2,000 | $242,340.00 | 427,025 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Dec 2 '24 | Sell | $122.49 | 53 | $6,491.97 | 6,596 | |
| Patil Neena M | JAZZ | EVP & Chief Legal Officer | Nov 8 '24 | Sell | $123.41 | 3,700 | $456,617.00 | 33,048 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Nov 1 '24 | Sell | $110.84 | 1,000 | $110,840.00 | 427,025 |
Latest Jazz Pharmaceuticals plc (Ireland) News
JAZZ Breaking Stock News: Dive into JAZZ Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Jazz Pharmaceuticals CEO Bruce Cozadd Plans to Retire
PR Newswire
a day ago
Jazz Pharmaceuticals Announces CEO Succession Plan
MT Newswires
2 days ago
Truist Securities Adjusts Jazz Pharmaceuticals Public Price Target to $220 From $200, Maintains Buy Rating
Simply Wall St.
4 days ago
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?
TipRanks
5 days ago
Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch
Zacks
7 days ago
5 High ROE Stocks to Buy as Volatility Weighs on Markets
Argus Research
7 days ago
JAZZ: Lowering target price to $132.00
MT Newswires
7 days ago
Jazz Pharmaceuticals Likely to Launch FDA-Approved Biliary Tract Cancer Treatment in 2025, RBC Says
Compare JAZZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.